Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors

NCT05071209 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05071209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05071209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 22, 2021
Completion date
March 31, 2026
Enrollment
31 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent alveolar rhabdomyosarcoma, recurrent ewing sarcoma, recurrent lymphoma, recurrent malignant solid neoplasm, refractory alveolar rhabdomyosarcoma, refractory ewing sarcoma, refractory lymphoma, refractory malignant solid neoplasm